Improved Bulbar Function in Amyotrophic Lateral Sclerosis after Nuedexta (Dextromethorphan and Quinidine) Treatment
Journal of the Korean Neurological Association
;
: 171-173, 2019.
Artículo
en Coreano
| WPRIM
| ID: wpr-766771
ABSTRACT
Nuedexta (dextromethorphan and quinidine) is an Food and Drug Administration approved medication for pseudobulbar affect. Interestingly, this drug was recently reported to improve speech, swallowing, and the ability to handle oral secretions along with emotional lability in amyotrophic lateral sclerosis (ALS) patients with bulbar symptoms. We report a Korean ALS patient whose bulbar function improved after administering Nuedexta for 6 months, extending therapeutic choice of approach in treating ALS patients.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Quinidina
/
United States Food and Drug Administration
/
Deglución
/
Dextrometorfano
/
Esclerosis Amiotrófica Lateral
Límite:
Humanos
Idioma:
Coreano
Revista:
Journal of the Korean Neurological Association
Año:
2019
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS